Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L01XX43

Erivedge(vismodegib)

Carcinoma, Basal Cell

Marketing Authorisation Holder: Roche Registration GmbH

EMA Authorisation: 12/07/2013

INN: vismodegib

Indication

Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Erivedge — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.